(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 December 2019 (12.12.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/234689 A1

(51) International Patent Classification:
A61K 31/4439 (2006.01) *A61P 43/00* (2006.01)
A61P 25/00 (2006.01)

(21) International Application Number:
PCT/IB2019/054743

(22) International Filing Date:
06 June 2019 (06.06.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
18382398.8 06 June 2018 (06.06.2018) EP

(71) Applicant: **MINORYX THERAPEUTICS S.L.** [ES/ES]; Av. Ernest Lluch 32, E-08302 Mataró Barcelona (ES).

(72) Inventors: **MARTINELL PEDEMONTE, Marc**; c/o Minoryx Therapeutics S.L., Av. Ernest Lluch 32, E-08302 Mataró Barcelona (ES). **PIZCUETA LALANZA, Maria Pilar**; c/o Minoryx Therapeutics S.L., Av. Ernest Lluch 32, E-08302 Mataró Barcelona (ES). **PINA LAGUNA, Guillem**; c/o Minoryx Therapeutics S.L., Av. Ernest Lluch 32, E-08302 Mataró Barcelona (ES). **MEYA, Uwe**; c/o Minoryx Therapeutics S.L., Av. Ernest Lluch 32, E-08302 Mataró Barcelona (ES). **BYE, Alan**; 4 Wain End, Horsham, Sussex RH12 5TQ (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

WO 2019/234689 A1

(54) **Title:** METHOD OF ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF 5-[[4-[2-[5-(1-HYDROXYETHYL)PYRIDIN-2-YL]ETHOXY]PHENYL]METHYL]-1,3-THIAZOLIDINE-2,4-DIONE

(57) **Abstract:** The present disclosure provides methods of treating a disease or disorder in a patient comprising administering 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione ("Compound (1)"), or a pharmaceutically acceptable salt thereof, to the patient, wherein the patient achieves a threshold steady-state plasma concentration of Compound (1). The present disclosure also provides methods of administering a therapeutically effective amount of Compound (1), or a pharmaceutically acceptable salt thereof, to a patient. Compound (1) is a PPAR-γ agonist that is used to treat a variety of diseases and disorders including, but not limited to, nonalcoholic steatohepatitis and central nervous system diseases, e.g., X-linked adrenoleukodystrophy, Friedreich's Ataxia.